Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Zomagen Biosciences Ltd.
Study ID
NCT06771115
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.

Key Dates

Start date
Jan 7, 2025
Status verified
Nov 2025
Primary completion
Sep 10, 2025
Completion
Sep 10, 2025

Study Design

Enrollment
176 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: VTX3232 Dose A
    VTX3232 Dose A
  • Placebo Comparator: Placebo
    Placebo
  • Experimental: VTX3232 Dose A in combination with semaglutide
    VTX3232 Dose A in combination with semaglutide
  • Experimental: Placebo in combination with semaglutide
    Placebo in combination with semaglutide

Primary Outcome Measure

Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completion [ Time Frame: Day 1 of treatment period through study completion, up to 16 weeks ]

Locations (14)

FacilityCityStateZIPSite coordinators
840005BirminghamAlabama35235-
840003Lake ForestCalifornia92630-
840011Long BeachCalifornia90815-
840001LargoFlorida33761-
840012OcoeeFlorida34761-
840016Port OrangeFlorida32127-
840014NewtonKansas67114-
840015MarreroLouisiana70072-
840017MarreroLouisiana70072-
840002AustinTexas78705-
840006DallasTexas75230-
840013San AntonioTexas78229-
840018San AntonioTexas78229-
840010WacoTexas76710-

Find similar trials in Birmingham, AL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
840005· Birmingham, AL840003· Lake Forest, CA840011· Long Beach, CA840001· Largo, FL840012· Ocoee, FL840016· Port Orange, FL

Related Studies